Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Side effects are rare but may include mild discomfort at the injection site, nausea, or digestive upset
Don't assume that what Medicare requires applies across all payers
DOI: 10.1161/HYPERTENSIONAHA.109.132522 Arsenian, M
Introduction A marked rise in the global prevalence of obesity and associated metabolic pathologies has been observed over the past 30 years ( Globally, more than 1 billion people are estimated to have NAFLD, including 83 million patients in the United States, making NAFLD the most common chronic liver disease in the US ( NASH is diagnosed histologically, based on the extent of steatosis, hepatocyte stress and damage (hepatocyte ballooning), immune infiltration (lobular inflammation), and degree of fibrosis ( While late-stage NASH greatly increases the risk of liver-related morbidity, NAFLD and NASH with less advanced fibrosis (i.e., F0F2) are associated with greatly increased risk of cardiovascular disease and related mortality ( Despite the unmet medical need, there is currently no approved therapy for NASH
